Development of new medicines is a time-consuming and costly process. New, innovative technologies that are able to speed up these developments are therefore of great importance to deliver medicines to patients as quickly as possible. In this research one of these new technologies, surface plasmon resonance imaging, has been evaluated as an efficient alternative to currently used technologies. In SPR, protein-protein interactions are measured, which can be used to distinguish a proper functioning molecule from molecules that do not bind to the target as desired. This makes the selection procedure for good medicines easier. In SPR imaging, many more interactions can be measured simultaneously (up to 96), which helps to increase the throughput for selection and enables the user to measure much more different binding properties at the same time. This has been applied to various steps throughout the entire development process and has resulted in various applications that may give a deeper understanding of the process and the medicine.